LTPA2017035I1 - Gydymas afukozintu anti-CD20 antikūnu kartu su bendamustinu - Google Patents

Gydymas afukozintu anti-CD20 antikūnu kartu su bendamustinu

Info

Publication number
LTPA2017035I1
LTPA2017035I1 LTPA2017035C LTPA2017035C LTPA2017035I1 LT PA2017035 I1 LTPA2017035 I1 LT PA2017035I1 LT PA2017035 C LTPA2017035 C LT PA2017035C LT PA2017035 C LTPA2017035 C LT PA2017035C LT PA2017035 I1 LTPA2017035 I1 LT PA2017035I1
Authority
LT
Lithuania
Prior art keywords
morphine
antibody
treatment
combination
Prior art date
Application number
LTPA2017035C
Other languages
English (en)
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41351729&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTPA2017035(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of LTPA2017035I1 publication Critical patent/LTPA2017035I1/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTPA2017035C 2009-08-14 2017-10-31 Gydymas afukozintu anti-CD20 antikūnu kartu su bendamustinu LTPA2017035I1 (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09010489 2009-08-14
PCT/EP2010/004939 WO2011018224A1 (en) 2009-08-14 2010-08-12 Combination therapy of an afucosylated cd20 antibody with bendamustine
EP10747168.2A EP2464382B1 (en) 2009-08-14 2010-08-12 Combination therapy of an afucosylated cd20 antibody with bendamustine

Publications (1)

Publication Number Publication Date
LTPA2017035I1 true LTPA2017035I1 (lt) 2017-11-27

Family

ID=41351729

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP10747168.2T LT2464382T (lt) 2009-08-14 2010-08-12 Gydymas afukozintu anti-cd20 antikūnu kartu su bendamustinu
LTPA2017035C LTPA2017035I1 (lt) 2009-08-14 2017-10-31 Gydymas afukozintu anti-CD20 antikūnu kartu su bendamustinu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP10747168.2T LT2464382T (lt) 2009-08-14 2010-08-12 Gydymas afukozintu anti-cd20 antikūnu kartu su bendamustinu

Country Status (34)

Country Link
US (4) US20110165151A1 (lt)
EP (1) EP2464382B1 (lt)
JP (3) JP5646626B2 (lt)
KR (1) KR101425736B1 (lt)
CN (2) CN102596245A (lt)
AR (1) AR077866A1 (lt)
AU (1) AU2010281866B2 (lt)
BR (1) BR112012002855A2 (lt)
CA (1) CA2769674C (lt)
CL (1) CL2012000391A1 (lt)
CR (1) CR20120036A (lt)
CY (2) CY1119251T1 (lt)
DK (1) DK2464382T3 (lt)
ES (1) ES2630158T3 (lt)
HK (1) HK1245145A1 (lt)
HR (1) HRP20170972T1 (lt)
HU (2) HUE033531T2 (lt)
IL (1) IL217753A (lt)
LT (2) LT2464382T (lt)
LU (1) LUC00045I2 (lt)
MA (1) MA33469B1 (lt)
MX (2) MX355849B (lt)
MY (1) MY163003A (lt)
NO (1) NO2017054I1 (lt)
NZ (1) NZ597666A (lt)
PL (1) PL2464382T3 (lt)
PT (1) PT2464382T (lt)
RS (1) RS56146B1 (lt)
SG (1) SG178324A1 (lt)
SI (1) SI2464382T1 (lt)
TW (1) TWI409079B (lt)
UA (1) UA110096C2 (lt)
WO (1) WO2011018224A1 (lt)
ZA (1) ZA201200830B (lt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201809892T4 (tr) 2003-11-05 2018-07-23 Roche Glycart Ag Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller.
WO2009012256A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
CL2008002085A1 (es) 2007-07-16 2008-11-21 Genentech Inc Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b
PL2247620T3 (pl) 2008-01-31 2017-08-31 Genentech, Inc. Przeciwciała anty-CD79B i immunokoniugaty i sposoby stosowania
MX2012013622A (es) 2010-05-31 2013-02-01 Ono Pharmaceutical Co Derivado de purinona.
FR2976811A1 (fr) * 2011-06-22 2012-12-28 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
LT2744826T (lt) * 2011-08-16 2022-04-25 Morphosys Ag Kombinuota terapija su anti-cd19 antikūnu ir purino analogu
CA3137321A1 (en) * 2011-08-16 2013-02-21 Morphosys Ag Combination therapy with an anti - cd19 antibody and a nitrogen mustard
FR2980110A1 (fr) * 2011-09-20 2013-03-22 Lfb Biotechnologies Combinaison d'anticorps anti-cd20 et de bendamustine
HUE031094T2 (en) 2011-11-29 2017-07-28 Ono Pharmaceutical Co Purinone derivative hydrochloride
CN103375132A (zh) * 2012-04-24 2013-10-30 长江大学 井下旋转冲击式钻井工具
US9963513B2 (en) 2013-02-05 2018-05-08 Engmab Sàrl Method for the selection of antibodies against BCMA
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
JP6335284B2 (ja) 2013-06-07 2018-05-30 ノルディック ナノベクター エーエスエー 抗原発現を上方制御するための方法
EP3122360B1 (en) 2014-03-25 2020-06-17 ONO Pharmaceutical Co., Ltd. Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
DK3262071T3 (da) 2014-09-23 2020-06-15 Hoffmann La Roche Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
JP6750613B2 (ja) 2015-04-09 2020-09-02 小野薬品工業株式会社 プリノン誘導体の製造方法
EP3670535A1 (en) 2015-08-03 2020-06-24 EngMab Sàrl Monoclonal antibodies against bcma
EP3257866A1 (en) * 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd
CN110167964B (zh) 2016-11-02 2023-12-01 百时美施贵宝公司 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3600416B1 (en) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
SG11202011545YA (en) 2018-05-23 2020-12-30 Celgene Corp Antiproliferative compounds and bispecific antibody against bcma and cd3 for combined use
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2020106754A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
JP7287048B2 (ja) 2019-03-27 2023-06-06 セイコーエプソン株式会社 ロボット
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
WO1999054342A1 (en) 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
WO1999060023A1 (en) 1998-05-15 1999-11-25 Imclone Systems Incorporated Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
ES2420835T3 (es) 1999-04-09 2013-08-27 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de las moléculas inmunofuncionales
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
MXPA04003798A (es) 2001-10-25 2004-07-30 Genentech Inc Composiciones de glicoproteina.
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
ES2744275T3 (es) 2002-10-17 2020-02-24 Genmab As Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple
SI1572744T1 (sl) 2002-12-16 2010-09-30 Genentech Inc Imunoglobulinske variante in njihove uporabe
KR101498588B1 (ko) 2003-01-22 2015-03-05 로슈 글리카트 아게 융합 구성체와 Ｆｃ 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도
KR20060012622A (ko) * 2003-05-16 2006-02-08 하이브리돈, 인코포레이티드 화학요법제와 함께 이뮤노머를 사용하는 상승적 암 치료방법
EP1648511A1 (en) 2003-07-29 2006-04-26 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
JP2007504245A (ja) 2003-09-05 2007-03-01 ジェネンテック・インコーポレーテッド 変更したエフェクター機能を有する抗体
TR201809892T4 (tr) 2003-11-05 2018-07-23 Roche Glycart Ag Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller.
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
EP1810035A4 (en) 2004-11-10 2010-03-17 Macrogenics Inc EFFECTOR FUNCTION OBTAINED BY CREATION BY BIOLOGICAL GENE OF FC ANTIBODY REGIONS
US20090215639A1 (en) 2005-04-26 2009-08-27 Bioren, Inc. Method of Producing Human IgG Antibodies with Enhanced Effector Functions
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
KR101460932B1 (ko) 2005-08-26 2014-11-12 로슈 글리카트 아게 변형된 세포 신호 활성을 가진 개질된 항원 결합 분자
EP2388272A1 (en) * 2005-10-21 2011-11-23 GTC Biotherapeutics, Inc. Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US20090110688A1 (en) * 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
US8802089B2 (en) * 2008-01-03 2014-08-12 Genmab A/S Monoclonal antibodies against CD32B
CN102355907A (zh) * 2009-01-16 2012-02-15 葛兰素史密斯克莱有限责任公司 用苯达莫司汀和抗cd20抗体的组合治疗癌症
EP2419470B1 (en) * 2009-04-15 2016-03-30 Invista Technologies S.à.r.l. Improving miscibility of otherwise immiscible compounds

Also Published As

Publication number Publication date
HRP20170972T1 (hr) 2017-09-22
CA2769674A1 (en) 2011-02-17
AU2010281866A1 (en) 2012-02-02
CR20120036A (es) 2012-04-18
CY1119251T1 (el) 2018-02-14
UA110096C2 (uk) 2015-11-25
JP5963013B2 (ja) 2016-08-03
MX2012001782A (es) 2012-04-19
MX355849B (es) 2018-05-02
KR20120054068A (ko) 2012-05-29
JP5646626B2 (ja) 2014-12-24
CY2017034I2 (el) 2018-02-14
PT2464382T (pt) 2017-06-30
AU2010281866B2 (en) 2016-05-12
TW201110980A (en) 2011-04-01
US20120315268A1 (en) 2012-12-13
US20140044705A1 (en) 2014-02-13
LT2464382T (lt) 2017-07-25
EP2464382B1 (en) 2017-05-03
KR101425736B1 (ko) 2014-08-01
IL217753A (en) 2016-10-31
WO2011018224A1 (en) 2011-02-17
HUS000498I2 (hu) 2021-03-29
LUC00045I1 (lt) 2017-11-03
CA2769674C (en) 2018-01-23
JP2013501740A (ja) 2013-01-17
EP2464382A1 (en) 2012-06-20
HK1245145A1 (zh) 2018-08-24
MA33469B1 (fr) 2012-07-03
ES2630158T3 (es) 2017-08-18
NZ597666A (en) 2013-10-25
AR077866A1 (es) 2011-09-28
SI2464382T1 (sl) 2017-08-31
US20110165151A1 (en) 2011-07-07
CN102596245A (zh) 2012-07-18
DK2464382T3 (en) 2017-07-17
SG178324A1 (en) 2012-03-29
RS56146B1 (sr) 2017-11-30
CN107261138A (zh) 2017-10-20
CL2012000391A1 (es) 2012-08-24
NO2017054I1 (no) 2017-10-26
JP2015071611A (ja) 2015-04-16
LUC00045I2 (lt) 2018-02-26
US20150093376A1 (en) 2015-04-02
IL217753A0 (en) 2012-03-29
ZA201200830B (en) 2012-10-31
CY2017034I1 (el) 2018-02-14
US20160166688A9 (en) 2016-06-16
TWI409079B (zh) 2013-09-21
HUS1700041I1 (hu) 2017-11-28
MY163003A (en) 2017-07-31
HUE033531T2 (hu) 2021-12-28
RU2012109445A (ru) 2013-09-27
JP2016222673A (ja) 2016-12-28
BR112012002855A2 (pt) 2016-11-01
PL2464382T3 (pl) 2017-09-29

Similar Documents

Publication Publication Date Title
LTPA2017035I1 (lt) Gydymas afukozintu anti-CD20 antikūnu kartu su bendamustinu
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
BR112013008905A2 (pt) mecanismo de dosagem e método de dosagem
DE112010001215A5 (de) Gurtaufrollersystem mit einsteuerglied
BR112014007243A2 (pt) composição, componentes e dispositivo de iluminação
ES1071902Y (es) Mecanismo de termosoldadura y precorte
FI20095999A0 (fi) Menetelmä pumppukäytön yhteydessä
DK2310037T3 (da) Conglutin-gamma as-medikament og -kosttilskudpatentkrav
DK2306097T3 (da) Ventilenhed med flere funktioner
ES1070576Y (es) Bionda perfeccionada
FI20095078A (fi) Menetelmä rullaimessa
TH128930B (th) สารที่มีฤทธิ์ในการฆ่าเชื้อและยับยั้งเชื้อ
FI8371U1 (fi) Järjestely taajuudenmuuttajassa
TH123099B (th) ไดไฮโดรไพราโซโลนที่ถูกแทนที่และการใช้ของมัน
TH105708B (th) ขวดพร้อมปั๊ม
UY3886Q (es) Configuración aplicada en dispensador
UY3960Q (es) Configuración aplicada en licuadora
TH103415B (th) ภาชนะ และภาชนะบรรจุโดยใช้สิ่งเดียวกันนี้
FI20096360A0 (fi) Bioliima ja puulevy
UY4071Q (es) Configuración aplicada en triciclo
TH100148B (th) ที่วางแขน
ES1069043Y (es) Recipiente perfeccionado
TH112302B (th) สารดูดซึม
ITLE20080006A1 (it) Vanga con fulcro
ITBA20080004A1 (it) Easy security - cavigliera e cintura